IDH-mutant Glioma: Vorasidenib improves PFS in phase 3 study IDH-mutant Glioma: Vorasidenib improves PFS in phase 3 study
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis. Learn more!Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Reactions to the INDIGO data Reactions to the INDIGO data
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Gliomagenesis Mechanism of Disease Gliomagenesis Mechanism of Disease
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis. Learn more!Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
The Journey to INDIGO The Journey to INDIGO
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
New drug effective at preventing growth of lower-grade brain tumors, clinical trial finds
(Source: Reuters: Health)
Source: Reuters: Health - June 5, 2023 Category: Consumer Health News Source Type: news
Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma
(MedPage Today) -- CHICAGO -- Oral vorasidenib monotherapy significantly improved progression-free survival (PFS), and delayed the time to next therapy, in patients with mutated, low-grade glioma, according to an interim analysis of the INDIGO... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2023 Category: Hematology Source Type: news
New drug delays progression of glioma, a deadly brain cancer
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
The team found the drug vorasidenib more than doubled progression-free survival in people with recurrent grade 2 glioma with IDH1 and IDH2 mutations. (Source: World Pharma News)
Source: World Pharma News - June 5, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Targeted Therapy Vorasidenib Offers Hope for Deadly Brain Tumors
Summary: A newly developed drug, Vorasidenib, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The international study found that patients taking Vorasidenib could go nearly 17 more months without their cancer worsening, postponing the need for…#vorasidenib #idh12 #ucla #timothycloughesy #2hydroxyglutarate #idh1 #benjaminellingson #jonssoncancercenter #ingomellinghoff #patrickwen (Source: Reuters: Health)
Source: Reuters: Health - June 4, 2023 Category: Consumer Health News Source Type: news
Vorasidenib Drug Delays Progression of Glioma Brain Cancer
A targeted therapy drug called vorasidenib had positive results in delaying progression of a specific form glioma, a slow-growing but deadly brain cancer (Source: Disabled World)
Source: Disabled World - June 4, 2023 Category: Disability Tags: Brain Cancers and Tumors Source Type: news
Treatment Breakthrough for an Intractable Brain Cancer
An experimental drug significantly delayed the growth of a pernicious type of brain tumor, a major advance in a field that has made little progress for decades. (Source: Reuters: Health)
Source: Reuters: Health - June 4, 2023 Category: Consumer Health News Source Type: news
Oral Drug for Brain Tumor Could Change Treatment Landscape Oral Drug for Brain Tumor Could Change Treatment Landscape
In patients with gliomas bearing IDH1/2 mutations, the brain barrier-crossing oral drug vorasidenib kept tumors at bay, and could be used instead of more toxic chemotherapies and radiation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 4, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Servier ’s Experimental Drug Slows Deadly Brain Tumor in Trial
(Source: Reuters: Health)
Source: Reuters: Health - June 4, 2023 Category: Consumer Health News Source Type: news
New drug delays progression of glioma, a deadly brain cancer
Key takeawaysA targeted therapy drug called vorasidenib had positive results in delaying progression of a specific form glioma, a slow-growing but deadly brain cancer.In a study of 331 people with the disease, the drug was effective in lengthening the period of time before the patients ’ cancer worsened, and with no observed adverse effects.New treatment approaches for glioma are needed because current treatments, including chemotherapy and radiation, can cause neurological deficits.In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a...
Source: UCLA Newsroom: Health Sciences - June 4, 2023 Category: Universities & Medical Training Source Type: news
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
BRISBANE, Calif., June 04, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the“Company”), a clinical-stage biopharmaceutical Company dedicated to developing and commercializing targeted... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 4, 2023 Category: Drugs & Pharmacology Source Type: news
FDA approves new PET tracer for prostate cancer imaging
The U.S. Food and Drug Administration (FDA) has approved Blue Earth Diagnostics...Read more on AuntMinnie.comRelated Reading:
Blue Earth touts clinical results
Blue Earth highlights results from PET tracer trial
PET tracer shows promise in imaging of brain tumors
Blue Earth touts PSMA radiotracer study
Blue Earth moves toward U.K. prostate radiopharmaceutical licensing (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 30, 2023 Category: Radiology Source Type: news
